Doximity Accelerates AI Investment in 2026, Targeting Multibillion-Dollar Market

Doximity, a digital platform for U.S. Medical professionals, plans to significantly increase its spending on artificial intelligence (AI) in 2026. This move is part of the company’s broader strategy to become a leading AI platform for doctors, according to Jeff Tangney, co-founder and CEO. During the recent earnings call for Doximity's fiscal 2026 fourth quarter and full year results, Tangney emphasized that this will be an "AI investment year" for the company.

The health tech firm aims to scale its clinical AI suite, which includes ambient notetaking tools like Scribe and a clinical AI assistant and medical search engine called Ask (formerly DoxGPT). These innovations are expected to drive strategic growth while acknowledging that increased spending will impact near-term margins. "We think that's the right trade," Tangney told investors, adding that AI search alone represents a multibillion-dollar total addressable market (TAM) beyond the existing pharmaceutical marketing budgets.

Strategic Growth and Monetization

Doximity’s AI-driven tools are designed to enhance physician workflow and improve clinical decision support. The company has already begun exploring ways to monetize its AI capabilities, particularly in the pharmaceutical marketing sector. Tangney noted that while the company expects minimal revenue contribution from AI this fiscal year, the long-term potential is significant.

The platform's extensive reach within the medical community-boasting a network of over 85% of U.S. Physicians-provides Doximity with a unique advantage. This widespread adoption can facilitate the integration of advanced AI tools and services, further solidifying its position in the market. The company’s existing offerings, such as telehealth solutions, clinician-to-patient communication tools, and digital faxing capabilities, serve a diverse range of paying customers including pharmaceutical manufacturers, health systems, and medical recruiting firms.

Investment Implications

Doximity's aggressive AI investment strategy is a clear signal of its commitment to innovation and market leadership. The company’s 2027 fiscal year began on April 1, and the increased R&D and compute spend will be complemented by enhanced brand marketing efforts. While this may temporarily affect profit margins, the long-term benefits are expected to outweigh the short-term costs.

Investors should watch for key milestones in Doximity's AI development and monetization plans. The success of these initiatives could not only boost the company’s revenue streams but also enhance its competitive edge in a rapidly evolving healthcare technology landscape. As AI continues to transform various sectors, Doximity’s strategic investments may position it as a frontrunner in this critical area.

Doximity's 2026 AI investment year is a bold move that aligns with the company’s vision of becoming a leading platform for physicians. The potential for significant long-term growth and market expansion makes this an important development for both the healthcare industry and investors alike.